stockportfolio.pro
Stocks / BVS vs RIGL
BVS vs RIGL
Bioventus Inc. and Rigel Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bioventus Inc. (BVS) | Rigel Pharmaceuticals, Inc. (RIGL) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $568.09M | $294.28M |
| Net income (latest FY) | $22.73M | $367.02M |
| Revenue growth (5y CAGR) | 12.1% | 22.1% |
| Net margin | 4.0% | 124.7% |
| Return on equity | 12.3% | 93.8% |
| P/E ratio | 21.2 | 1.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 2 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BVS — free Open RIGL — freeFrequently asked questions
Which is bigger, BVS or RIGL?
Bioventus Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, BVS or RIGL?
Over the last five fiscal years, Rigel Pharmaceuticals, Inc. grew revenue faster — 22.1%/yr versus 12.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.